pharmaceuticals

The FDA had been expected to decide by next week, but a back-and-forth between state and federal officials about details of the proposal means the wait will continue, a court document says.

A Tampa-area mom couldn't watch her 9-year-old's leukemia go untreated. She started campaigning to fix a broken system and get patients the treatments they need in the face of drug shortages.

The point isn’t that Donald Trump managed drug shortages badly as president or that Joe Biden is handling them badly now, experts said. Many factors contribute to the problem.

A federal audit found lax oversight and multiple cases of child welfare workers failing to follow state regulations on psychotropic or opioid medication.

The agency reiterated its longstanding position that a lone study by drugmaker Brainstorm doesn't provide convincing evidence that its stem cell-based therapy helps patients with amyotrophic lateral sclerosis.

Thousands of patients with autoimmune diseases who rely on Humira, with a list price of $6,600 a month, could get financial relief from new low-cost rivals. So far, the pharmacy benefit managers that control drug prices have not delivered on those savings.

The Biden administration unveiled the first 10 drugs subject to price negotiations, taking a swipe at the pharmaceutical industry. But what does it mean for patients?

The government will negotiate new prices for the commonly prescribed drugs, but the cuts won't take effect until 2026. In the meantime, drug-makers are fighting the negotiations with lawsuits.

Brand-name drug prices in the U.S. — more than three times the price in other developed countries — are related neither to the amount of research and development nor their therapeutic value, research shows.

The state alleges the federal agency violated the Freedom of Information Act. The revised lawsuit includes allegations that the FDA did not properly respond to a records request submitted in May.